Breast Biopsy Market Overview

The global Breast Biopsy Market was calculated at USD 1129 million in 2021 and is estimated to reach USD 1992 million by 2028, growing at a CAGR of 5.6% during the forecast period of 2022 to 2028. The increase in awareness regarding early detection of breast cancer and the improved reimbursement scheme further influence the market growth. Further, the rise in population, surge in healthcare expenditure and rise in endeavors by public organizations towards female health problems thoroughly affect the breast biopsy devices market.

What is Breast Biopsy?

A breast biopsy is a test conducted to extract tissue or fluid from a diseased place of the patient’s body, while the extracted sample is further analyzed to check the presence of breast cancer. There are different types of biopsy methods depending on the product, such as vacuum-assisted biopsy, core needle biopsy, and fine-needle aspiration biopsy, recommended by the doctor based on location and size and different elements of the breast irregularity. The different methods of the biopsy market work fast, and it is easy. As a result, the results are fast and correct.

Growth Drivers

Increasing Cases of Breast Cancer

Breast cancer is among the familiar diseases in progressive and developing countries. According to the American Cancer Society, breast cancer is the second-leading reason of cancer-related deaths worldwide. For example: In the US, one in eight women creates invasive breast cancer for her lifetime. According to the American Cancer Society and the National Cancer Institute, in 2018, over 265,000 new patients with invasive breast cancer were diagnosed among women in the US, with 63,960 new cases of non-invasive breast cancer. In Canada, as many as 26,300 women were diagnosed with breast cancer in 2017, expressing 25% of new cancer cases (Source: Canadian Cancer Society), i.e., 72 Canadian women are diagnosed with breast cancer every day. The increasing number of breast cancer patients has caused governments across the globe to increase awareness regarding the implication of early detection of breast cancer, which is expected to drive market growth.

Opportunities

The emergence of liquid biopsy and favorable clinical practices

Liquid biopsy is a blood test that aids physicians in determining cancer cells or DNA elements of tumors in blood. This technique stops the need to carry out surgical and needle biopsies and allows physicians to identify cancer in the early stages. It also catches the full genetic complexity of tumors and limits the chances of cancer cells chances to spread to other parts of the body. Currently, different players are conducting clinical trials to establish the usefulness and efficiency of liquid biopsy in oncology; the favorable results are anticipated to create new opportunities for players operating in the market.

Restraints

Chance of infections with the usage of biopsy needles

Biopsy needle methods, such as core and fine needle procedures, help radiologists and surgeons examine irregularities at a particular site. However, patients can contract infections during these processes, involving cuts and incisions to remove tissue samples. In several cases, biopsy needles are reused, increasing the chance of infection during these procedures. While healthcare management and product manufacturers do not advise the reuse of some needles, the practice is still prevalent, especially in developing countries. Thus, to avoid the chance of infections from these methods, healthcare providers and patients may opt for alternative diagnostic methods for target situations.

Pre Covid-19 Impact on Global Breast Biopsy Market

Before the covid-19 outbreak, Novel biopsy methods and the beginning of new product approvals provides minimally invasive procedures. A 6mm Bergstrom side-cutting biopsy needle was believed a successful instrument to obtain large pieces of tissue under the guidance of ultrasound. Such new instruments and techniques have seriously affected the overall growth of the Breast biopsy market. In recent years, increasing incidences of breast cancer have been the primary growth attributing factor for the Breast biopsy market. Over 265,000 cancer susceptive cases were diagnosed in 2018 and assumed out over 63,960 non-invasive methods during the year. Such reports stimulate the overall growth of the market.

Covid-19 Impact on Global Breast Biopsy Market

During the covid-19 period, the impact of the pandemic and the lockdown it started is visible in various industries, including the breast biopsy market. The execution of new guidelines and restrictions is hindering the growth of this industry. Moreover, restricted access to clinics, social distancing, the lockdown of the population, which results in a slow-down in patient flow and referrals, has also affected the market growth.

Post Covid-19 Impact on Global Breast Biopsy Market

After the covid-19 period, the recommendation for breast biopsy, especially the mammography-guided stereotactic biopsy, has rapidly expanded the adoption rate in developed countries. Moreover, the rationalizing usage of mammography complemented by the other breast examinations has helped as a pillar for screening breast cancer-driving the market growth.

By Product Segmental Analysis

The market is segmented into Needles, Tables, and Assay Kit based on product segmental analysis. The biopsy needle segment held a major share of the market. The biopsy needles segment is anticipated to hold a major share of the breast biopsy market due to the rising adoption of image-guided techniques in developed and developing countries and the introduction of technologically advanced and novel designs. For example, the tri-axial needle is composed of a pincer needle on the outer side, an outer cutting needle, and a sharp stylet on the inner side.

By Type Segmental Analysis

Based on type segmental analysis, the market is segmented into Needle Biopsy {CNB, FNAB, VAB}, Liquid Biopsy {CTC, ctDNA}, and Guidance {Image-Guided {Mammography, Liquid Biopsy}}. The liquid biopsy segment is expected to record the highest growth over the forecast period of 2021-2028. Liquid biopsy has arisen as a revolutionary technology that delivers new sizes to oncology diagnostics. The significant growth of the segment is attributed to the growing adoption of novel NGS-based assays and droplet digital PCR technology to serve liquid biopsies in most developed countries.

By End-User Segmental Analysis

Based on the end-user segmental analysis, the market is segmented into Hospitals and Diagnostic Centers. Hospitals are undertaking novel endeavors to raise public awareness about breast cancer and the clinical benefits of its early diagnosis through screening programs. These initiatives to increase awareness about early detection and diagnosis of breast cancer will fuel the demand for breast biopsy systems, further driving market growth in the hospital segment.

By Regional Segmental Analysis

Based on the regional segmental analysis, the market is segmented into North America, Europe, Asia-Pacific, South America and The Middle East & Africa. Asia Pacific region market to record the highest growth for the breast biopsy market. The healthcare infrastructure in rising economies such as China, India, and South Korea is growing fast, offering major investments in developed systems (including liquid breast biopsy and vacuum-assisted biopsy instruments, among others) by hospitals and breast care centers.

Competitors Analysis

The companies include Hologic Inc., Leica Biosystems Nussloch GmbH, C.R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule Medical Devices LLC, Intact Medical Corporation, Galini SRL and other prominent players in the global breast biopsy market. Key Stakeholders

• Market research and consulting firms
• Breast Biopsy Medical Association
• Local Governments
• Regulatory bodies
• Breast Biopsy Market
• Service Providers

Recent Development

• In 2018, Hologic acquired the European CE mark support for its Brevera Breast Biopsy System with CorLumina Imaging Technology. This method is designed to improve biopsy accuracy with real-time imaging, enhance patient fulfillment, and streamline workflow in the biopsy suite.
• In 2017, Hologic declared the launch of its Brevera Breast Biopsy System with CorLumina Imaging Technology for commercial availability in the US. This system is developed to improve biopsy accuracy with real-time imaging, enhance patient knowledge, and streamline the biopsy procedure from start to finish.

Scope of the Report

Report Attribute	Details
Market Size Value in 2021	USD 1129 million
The revenue forecast in 2028	USD 1992 million
Growth Rate	CAGR of 5.6% from 2022 to 2028.
Historical data	2017 – 2020
Base Year	2021
Forecast period	2022 – 2028
Region covered	North America, Europe, Asia-Pacific, South America, and Middle East & Africa
Key companies Profiled	The Companies include Hologic Inc., Leica Biosystems Nussloch GmbH, C.R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule Medical Devices LLC, Intact Medical Corporation, Galini SRL are the key players.

Market Modelling

By Product

• Needles
• Tables
• Assay Kit

By Type

• Needle Biopsy (CNB, FNAB, VAB)
• Liquid Biopsy (CTC, ctDNA)
• Guidance (Image-Guided (Mammography, Liquid Biopsy)

By End-User

• Hospitals
• Diagnostic Centers

By Region

• North America
• Europe
• Asia-Pacific
• South America
• The Middle East & Africa

Agricultural Microbial Market

Fabric Printing Machine Market

Spare Parts Market

Automotive After Market

PV Glass Market

Industrial Hybrid Stepper Motors Market

Vaccines Market

Anti-Corrosion Tape Market

Paper Core Market

Ultra-Wideband Technology Market